Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: Impact of HIV and antiretroviral therapy

Clinical Infectious Diseases

Volumn 59, Issue 12, 2014, Pages 1798-1804

  Narendran, Gopalan ^a   Menon, Pradeep Aravindan ^a   Venkatesan, Perumal ^a   Vijay, Krishnamoorthy ^a   Padmapriyadarsini, Chandrasekaran ^a   Ramesh Kumar, Santhanakrishnan ^a   Bhavani, Kannabiran Perumal ^a   Sekar, Lakshmanan ^a   Gomathi, Sivaramakrishnan Narayan ^a   Chandrasekhar, Chockalingam ^b   Kumar, Satagopan ^b   Sridhar, Rathinam ^c   Swaminathan, Soumya ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^b Government Hospital of Thoracic Medicine   (United States)

^c Government Stanley Hospital   (India)

Author keywords

acquired rifampicin resistance; drug resistant tuberculosis; HIV; intermittent therapy; tuberculosis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ACQUIRED RIFAMPICIN RESISTANCE; ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; VIRUS LOAD; ADOLESCENT; ANTIBIOTIC RESISTANCE; COMPLICATION; DRUG EFFECTS; HIV INFECTIONS; RANDOMIZED CONTROLLED TRIAL; TUBERCULOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; RIFAMPIN; RISK FACTORS; TUBERCULOSIS; YOUNG ADULT;

EID: 84924978316     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu674     Document Type: Article

References (31)

1. World Health Organization. Global tuberculosis report 2013; WHO report 2013. Available at: http://apps.who.int/iris/bitstream/10665/91355/ 1/9789241564656-eng.pdf. Accessed 31 January 2014.
2. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4:796-806.
3. O'Donnel MM, Carvalho SS, Gadelha AJ, et al. Poor response to tuberculosis treatment with regimens without rifampicin in immunosuppressed AIDS in patients. Braz J Infect Dis 2002; 6:272-75.
4. Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with onceweekly rifapentine and isoniazid. Lancet 1999; 353:1843-7.
5. Nahid P, Gonzalez LC, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175:1199-206.
6. Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 2010; 181:743-51.
7. Tuberculosis Research Centre. Low rate of emergence of drug resistance in sputum positive patients treated with short course chemotherapy. Int J Tuberc Lung Dis 2001; 5:40-5.
8. Central Tuberculosis Division, Directorate General of Health Services, Ministry of Health and FamilyWelfare. TB India 2013-RNTCP Annual status report. Available at: http://www.tbcindia.nic.in/pdfs/tb% 20india%202013.pdf. Accessed 6 November 2011.
9. Banu Rekha VV, Rajaram K, Kripasankar AS, et al. Efficacy of the 6-month thrice-weekly regimen in the treatment of new sputum smearpositive pulmonary tuberculosis under clinical trial conditions. Natl Med J India 2012; 25:196-200.
10. Vashishtha R, Mohan K, Singh B, et al. Efficacy and safety of thrice weekly DOTS in tuberculosis patients with and without HIV co-infection: an observational study. BMC Infect Dis 2013; 13:468.
11. Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010; 50:1288-99.
12. World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. WHO/HTM/TB/2009.420. Geneva, Switzerland: WHO, 2010.
13. Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of once-daily nevirapine-or-based antiretroviral therapy in HIVassociated tuberculosis: a randomized clinical trial. Clin Infect Dis 2011; 53:716-24.
14. Narendran G. Comparing daily vs. intermittent regimen of ATT in HIV with pulmonary tuberculosis, 2009. Available at: http://clinicaltrials. gov/ct2/show/NCT00933790?term=Daily+Vs+intermittent+ATT+in +HIV&rank=1. Accessed 25 January 2013.
15. Allen B, Baker FJ. Mycobacteria: isolation, identification and sensitivity testing. London: Butterworth, 1968.
16. Canetti G, FoxW, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41:21-43.
17. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365: 1492-501.
18. World Health Organization (WHO). Rapid advice: antiretroviral therapy forHIVinfection in adults and adolescents,November 2009.Available at: http://www.who.int/hiv/pub/arv/advice/en/. Accessed 30 January 2013.
19. Korenromp EL, Scano F, Williams CD, et al. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampicin treatment: an analytical review. Clin Infect Dis 2003; 37:101-12.
20. Narayanan S, Swaminathan S, Supply P, et al. Impact of HIV infection on the recurrence of tuberculosis in south India. J Infect Dis 2010; 201: 691-703.
21. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009; 6:e1000146.
22. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40:1481-91.
23. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis 2004; 38:280-3.
24. Burman W, Benator D, Vernon A, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173:350-6.
25. Swaminathan S, Narendran G, Venkatesan P, et al. Acquired rifampicin resistance in HIV infected and uninfected patients with tuberculosis treated with thrice weekly short course regimens. In: 16th Conference on Retrovirus and Opportunistic Infections, Montreal, Canada, 2009. Abstract no. P-130.
26. Porco TC, Oh P, Flood JM. Antituberculosis drug resistance acquired during treatment: an analysis of cases reported in California, 1994-2006. Clin Infect Dis 2013; 56:761-9.
27. Mitchison DA. Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 167:1298-9.
28. Li J, Munsiff SS, Driver CR, et al. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampinor rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis 2005; 41:83-91.
29. Lew W, Pai M, Oxlade O, et al. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008; 149:123-34.
30. Ahmad Khan F, Minion J, Al-Motairi A, et al. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin Infect Dis 2012; 55:1154-63.
31. Narendran G, RameshKumar S, Venkatesan P, et al. Early bacteriological, clinical and radiographic response to thrice weekly compared to daily anti-tuberculosis treatment among HIV-infected tuberculosis patients [abstract s-126]. In: 20th Conference on Retrovirus and Opportunistic Infections, Atlanta, Georgia, 2013.